Aurora A and B Kinases - Targets of Novel Anticancer Drugs

Author(s): Silvana Libertini, Antonella Abagnale, Carmela Passaro, Ginevra Botta, Giuseppe Portella

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 5 , Issue 3 , 2010

Become EABM
Become Reviewer
Call for Editor


The Aurora Kinases are highly related serine-threonine kinases, essential for accurate and equal segregation of genomic material during mitosis. A large number of studies have linked the aberrant expression of Aurora kinases to cancer, leading to the development of specific Aurora kinases inhibitors. Several small molecules inhibit with a similar efficacy both Aurora A and Aurora B, however, in most cases the effects resemble Aurora B disruption by genetic methods, indicating that Aurora B represents an effective therapeutic target. These drugs are currently under preclinical or clinical evaluation and are reviewed in this article. The relevant patents are discussed.

Keywords: Aurora kinase, Aurora B, serine-threonine kinase, mitosis, cytokinesis, cancer, inhibitors

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [219 - 241]
Pages: 23
DOI: 10.2174/157489210791760517
Price: $65

Article Metrics

PDF: 23